Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas

Abstract

Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC). It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis. We studied ret mRNA expression in PTC from Norwegian patients. Using RT–PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes confirmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wild-type Ret protein in PTC. Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC. Multiple alternative ret splicing variants were detected in PTC. Four novel ret splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cystein-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the ret mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays confirmed the presence of ret alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC. Transcriptional up-regulation and post-transcriptional mechanisms of c-ret RNA processing may contribute to differences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Airaksinen MS, Titievsky A and Saarma M. . 1999 Mol. Cell Neurosci. 13: 313–325.

  • Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekete C and Munnich A. . 1995 Hum. Mol. Genet. 4: 1381–1386.

  • Bunone G, Uggeri M, Mondellini P, Pierotti MA and Bongarzone I. . 2000 Cancer Res. 60: 2845–2849.

  • Carson-Walter EB, Smith DP, Ponder BA, Baylin SB and Nelkin BD. . 1998 Oncogene 17: 367–376.

  • Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M and Romeo G. . 1993 Biochem. Biophys. Res. Commun. 196: 1288–1295.

  • de Nigris F, Visconti R, Cerutti J, Califano D, Mineo A, Santoro M, Santelli G and Fusco A. . 1998 Cancer Res. 58: 4745–4751.

  • Feinberg AP and Vogelstein B. . 1983 Anal. Biochem. 132: 6–13.

  • Fluge O, Akslen LA, Haugen DR, Varhaug JE and Lillehaug JR. . 2000 Int. J. Cancer 87: 763–770.

  • Ishizaka Y, Shima H, Sugimura T and Nagao M. . 1992 Oncogene 7: 1441–1444.

  • Ivanchuk SM, Eng C, Cavenee WK and Mulligan LM. . 1997 Oncogene 14: 1811–1818.

  • Ivanchuk SM, Myers SM and Mulligan LM. . 1998 Oncogene 16: 991–996.

  • Kwok JB, Gardner E, Warner JP, Ponder BA and Mulligan LM. . 1993 Oncogene 8: 2575–2582.

  • Lam AK, Montone KT, Nolan KA and LiVolsi VA. . 1998 Hum. Pathol. 29: 565–568.

  • Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ and Ploos VAH. . 1996 Hum. Genet. 97: 11–14.

  • Learoyd DL, Messina M, Zedenius J, Guinea AI, Delbridge LW and Robinson BG. . 1998 J. Clin. Endocrinol. Metab. 83: 3631–3635.

  • Lorenzo MJ, Eng C, Mulligan LM, Stonehouse TJ, Healey CS, Ponder BA and Smith DP. . 1995 Oncogene 10: 1377–1383.

  • Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA and Smith DP. . 1997 Oncogene 14: 763–771.

  • Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C and Safar A. . 1994 Hum. Mol. Genet. 3: 2163–2167.

  • Myers SM, Eng C, Ponder BA and Mulligan LM. . 1995 Oncogene 11: 2039–2045.

  • Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, and Fagin JA. . 1997 Cancer Res. 57: 1690–1694.

  • Santoro M, Melillo RM, Carlomagno F, Visconti R, De Vita G, Salvatore G, Fusco A and Vecchio G. . 1999 Biochimie 81: 397–402.

  • Santoro M, Sabino N, Ishizaka Y, Ushijima T, Carlomagno F, Cerrato A, Grieco M, Battaglia C, Martelli ML and Paulin C. . 1993 Br. J. Cancer 68: 460–464.

  • Santoro M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A and Di Fiore PP. . 1994 Mol. Cell Biol. 14: 663–675.

  • Tahira T, Ishizaka Y, Itoh F, Sugimura T and Nagao M. . 1990 Oncogene 5: 97–102.

  • Takahashi M, Buma Y and Hiai H. . 1989 Oncogene 4: 805–806.

  • Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H and Hiai H. . 1988 Oncogene 3: 571–578.

  • Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML and Fusco A. . 1998 Clin. Cancer Res. 4: 287–294.

  • Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE and Rosenthal A. . 1996 Nature 382: 80–83.

  • van Weering DH and Bos JL. . 1998 Recent Results Cancer Res. 154: 271–281.

  • Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M and Fusco A. . 1995 Oncogene 11: 1207–1210.

  • Visser M, Sonneveld RD, Willemze R and Landegent JE. . 1996 Br. J. Haematol. 94: 236–241.

  • Williams GH, Rooney S, Thomas GA, Cummins G and Williams ED. . 1996 Br. J. Cancer 74: 585–589.

  • Wilson KF, Fortes P, Singh US, Ohno M, Mattaj IW and Cerione RA. . 1999 J. Biol. Chem. 274: 4166–4173.

  • Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane WM and Rothstein JL. . 1997 Laryngoscope 107: 95–100.

  • Xing S, Tong Q, Suzuki T and Jhiang SM. . 1994 Biochem. Biophys. Res. Commun. 205: 1526–1532.

Download references

Acknowledgements

The authors thank Ove Bruland for discussions and Ms Rita Holdhus and Ms Hildegard Kanestrøm for technical assistance. This work was supported by grants from The Norwegian Cancer Society (Ø Fluge, DRF Haugen and JE Varhaug), The Norwegian Research Council (JR Lillehaug), and the Cancer Locus, Faculty of Medicine, University of Bergen.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fluge, Ø., Haugen, D., Akslen, L. et al. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene 20, 885–892 (2001). https://doi.org/10.1038/sj.onc.1204161

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204161

Keywords

This article is cited by

Search

Quick links